Drawing on resources from the Lovelace Respiratory Research Institute (LRRI) and associated companies, a not-for-profit preclinical contract research organization called Lovelace Biomedical is now offering services for pre-clinical development. The new company’s services include toxicology, pharmacology, bioanalytical/analytical chemistry, and formulation for a range of dosage forms, including DPIs, MDIs, and nebulized products.
In addition to expertise in inhaled therapies for asthma, COPD, and cystic fibrosis, Lovelace Biomedical has special expertise in aerosol delivery of alternative tobacco products.
Lovelace Biomedical VP of Applied Science Jake McDonald commented, “Going back more than four decades, the Lovelace family of companies has been recognized as leader in advancing medical research that requires deep expertise in respiratory and inhalation science. As a contract research organization, Lovelace Biomedical draws on this legacy to help pharmaceutical and biotechnology companies advance potential new therapies and devices into clinical testing; this often includes formulation development, measuring efficacy and toxicity in novel ways and developing new animal models and tools to support the development of new potential products. We have a team of experts at all steps of preclinical research needed take a product forward to ultimately help patients.”
The company will operate out of 300,000 sq ft laboratory facilities in Albuquerque, New Mexico, with 500 employees.
Read the Lovelace Biomedical press release.
